Midwest |​ Southwest |​ Southeast 

---

Cardiac Amyloidosis: From Missed and Undiagnosed, to Common and Treatable

Program Director: Mouaz Al-Mallah, MD, FASNC

Fee: ​Free for members, $75 for non-members, Join ASNC and Save
Credits: Earn 3.25* AMA PRA Category 1 Credits™​ or 4.5* ARRT Category A CE credits 


 

*Credits subject to change
 

Agenda     Time Title Speaker 8:30 am - 8:35 am  Welcome Mouaz Al-Mallah, MD 8:35 am - 9:00 am  ATTR Cardiac Amyloidosis: Clinical Presentation and Outcomes Juan C. Lopez-Mattei, MD 9:00 am - 9:20 am  The Role of Echocardiography and Cardiac MRI in Suspected Cardiac Amyloidosis Faisal Nabi, MD 9:20 am - 9:45 am  PYP Imaging: Diagnostic Accuracy and Pitfalls John Mahmarian, MD 9:45 am - 10:00 am  Cardiac PET in Suspected Cardiac Amyloidosis Mouaz Al-Mallah, MD 10:00 am - 10:20 am  Management of ATTR Amyloidosis Barry Trachtenberg, MD 10:20 am - 10:40 am  Panel Discussion   10:40 am - 11:00 am  Break   11:00 am - 11:45 am  Case Presentations Mohammad Chamsi Pasha, DO Ali Agha, MD Alpana Senapati, DO Moderator: Mouaz Al-Mallah, MD   Panel: Faisal Nabi, MD Mahwash Kassi, MD John Mahmarian, MD Barry Trachtenberg, MD 11:45 am - Noon  Final Remarks Mouaz Al-Mallah, MD

 
This program is jointly sponsored by the American Society of Nuclear Cardiology and Houston Methodist.

---

Register for upcoming webinars and view our extensive archives and portfolio of online education available for CME/CE credits.

---

South Florida Cardiac Amyloid Symposium
Wake up and Look Around
Towards Early Recognition, Diagnosis and Treatment of Cardiac Amyloidosis

Saturday, Oct. 31
8:00 am to Noon (EDT)
Program Director: David Wolinsky, MD, MASNC

Fee: ​Free for members, $75 for non-members, Join ASNC and Save
Credits: Earn 4.5* AMA PRA Category 1 Credits™​ or 4.5* ARRT Category A CE credits  

---

Motown Virtual Amyloidosis Symposium

Join us for the Motown Virtual Amyloidosis Symposium, directed by Karthik Ananthasubramaniam, MD, FASNC, of the Henry Ford Health System, and Aiden Abidov, MD, of Wayne State University School of Medicine.

The program includes two info-packed symposia giving you a full overview of amyloidosis from diagnosis to testing and treatment options to case reviews with expert faculty.

Be part of a focused discussion on where cardiologists and allied professionals stand with diagnosing and treating cardiac amyloidosis in Michigan.

Learn insights from discovery studies and results from patients to help determine:

• Which patients to screen and what steps to take
• How to properly diagnosis and treat patients
• Which patients to refer and where
• How collaboration in the Michigan-area medical community can be increased

Motown Virtual Amyloidosis Symposium: Part 1
August 15, 2020 - 10:00 am-12:00 pm (EDT)

Part 1 will introduce you and your provider network to the field's rapidly evolving framework for cardiac amyloidosis -- clearing up misconceptions; explaining connections among HFpEF, AS and amyloidosis; and updating you on breakthrough testing and management options.
 

Agenda - August 15, 2020 - Part 1: Cardiac Amyloidosis 101
Time	Title	Speaker
10:00 am	Introduction/Housekeeping	Karthik Ananthasubramaniam, MD
10:05 am	Light Chain Amyloidosis: An Overview	Jeffrey Zonder, MD
10:20 am	Transthyretin Cardiac Amyloidosis: An Overview	Karthik Ananthasubramaniam, MD
10:35 am	Transthyretin Amyloid Neuropathy	Naganand Sripathi, MD
10:50 am	HFpEF, Aortic Stenosis, and Amyloidosis: What is the Connection	Luis Afonso, MD
11:05 am	Genetic Testing, Screening Family Members in TTR Amyloid Diagnosis	Jennifer Cowger, MD
11:20 am	Management Options in TTR Amyloidosis	Aiden Abidov, MD
11:35 am	Organ Transplantation	Celeste Williams, MD
11:45 am	Discussion. Q&A and Wrap-up	Drs. Ananthasubramaniam and Abidov

 

Motown Virtual Amyloidosis Symposium: Part 2
August 29, 2020 - 10:00 am-12:00 pm (EDT)

Fee: ​Free for members, $50 for non-members, Join ASNC and Save
Credits: Earn 2 AMA PRA Category 1 Credits™​

Part 2 will review how multimodality imaging is transforming cardiac amyloidosis diagnosis, with case-based presentations showcasing how echo, Tc99m-PYP, MRI, and PET are changing the care paradigm for patients.
 

Agenda - August 29, 2020 – Part 2: Multimodality Imaging in Diagnosis of Cardiac Amyloidosis: Case-Based Review
Time	Title	Speaker
10:00 am	Introduction/Housekeeping	Karthik Ananthasubramaniam, MD
10:05 am	Echocardiography: What We Need to Know and Look For	TBD
10:20 am	Technetium-99m Pyrophosphate Imaging (PYP): Nuts and Bolts	Karthik Ananthasubramaniam, MD
10:45 am	Cardiac MRI Imaging: Current and New Tools	TBD
11:05 am	New Imaging Modalities in the Pipeline: PET	Karthik Ananthasubramaniam, MD
11:15 am	Challenging and Interesting Cases in Amyloidosis	TBD, Aiden Abidov, MD, Luis Afonso, MD
11:55 am	Discussion and Wrap-up	Drs. Ananthasubramaniam and Abidov

The Cardiac Amyloidosis: On the Road programs will:

• Address the knowledge, competence and performance gaps in disease epidemiology, pathophysiology, diagnosis and treatments for ATTR-CM. 
• Improve diagnosis across all patient populations, timely referral to amyloid experts, and knowledge of treatment options with the goal of improving outcomes of patients with ATTR-CM. 
• Enhance the understanding of the overlap of cardiac amyloidosis with other conditions leading to a misdiagnosis or delayed diagnosis.  
• Focus on the diagnostic algorithm, including the appropriate use of Tc-99m PYP, and the importance of image interpretation alongside other clinical findings. 
• Discuss the central role of Tc-99m PYP imaging and the protocols for acquisition, processing and interpretation to ensure understanding of the procedure and the data it provides.
   

Participants of these programs will be able to:

• Describe amyloidosis, including specific types, cardiac features and disease burden.
• Identify barriers to identification and diagnosis of patients suspected of ATTR.
• Recognize patients at risk for hereditary ATTR (hATTR) and wild-type ATTR (wtATTR).
• Summarize the diagnostic evaluation for cardiac amyloidosis including the differential diagnosis. 
• Provide details of Tc-99m PYP including imaging protocol, semi-quantitative and quantitative scoring, interpretation including identifying false positive and false negative studies, and components of an appropriate report. 
• Demonstrate understanding of current treatments for patients with ATTR-CM.

If you have any questions about registration, please contact info@asnc.org

These programs are supported by educational grants from Pfizer.
 

More Cardiac Amyloidosis Resources